Relationship of diabetes mellitus with prognostic factors in breast cancer.
| Title: | Relationship of diabetes mellitus with prognostic factors in breast cancer. |
|---|---|
| Authors: | Ozer SP; Department of Pathology, Izzet Baysal Training and Research Hospital, Bolu 14030, Türkiye.; Keyif F; Department of General Surgery, Abant Izzet Baysal University, Bolu 14030, Türkiye.; Bolat F; Department of General Surgery, Abant Izzet Baysal University, Bolu 14030, Türkiye.; Ozer B; Department of General Surgery, Abant Izzet Baysal University, Bolu 14030, Türkiye.; Aktas G; Department of Internal Medicine, Abant Izzet Baysal University, Bolu 14030, Türkiye. draliaktas@yahoo.com. |
| Source: | World journal of experimental medicine [World J Exp Med] 2025 Sep 20; Vol. 15 (3), pp. 108318. Date of Electronic Publication: 2025 Sep 20 (Print Publication: 2025). |
| Publication Type: | Journal Article |
| Language: | English |
| Journal Info: | Publisher: Baishideng Publishing Group Country of Publication: United States NLM ID: 101618808 Publication Model: eCollection Cited Medium: Print ISSN: 2220-315X (Print) Linking ISSN: 2220315X NLM ISO Abbreviation: World J Exp Med Subsets: PubMed not MEDLINE |
| Imprint Name(s): | Publication: 2014-: Pleasanton, CA : Baishideng Publishing Group; Original Publication: Hong Kong, China : Baishideng Publishing Group Co., Limited |
| Abstract: | Background: Hyperglycemia secondary to diabetes can lead to organ failure unless properly controlled, and it is associated with numerous health issues, particularly metabolic problems. Breast cancer is one of the most common malignancies in females worldwide and represents a major health concern due to its morbidity and mortality. The progression of the disease and the response to treatment depend on numerous variables, including both tumor biology and patient-related factors. Key prognostic indicators include age, tumor size, lymph node involvement, histological type, hormone receptor status, and expression of biomarkers such as HER2.; Aim: To investigate the relationship between preoperative blood glucose levels and cancer prognostic factors in patients diagnosed with breast cancer.; Methods: In this study patients diagnosed with breast cancer were classified into two groups: Those with blood glucose levels < 125 mg/dL and those with levels > 125 mg/dL. Estrogen and progesterone receptor positivity, Ki-67 percentage, Cerb2 positivity, number of positive lymph nodes, and presence of lymphovascular invasion were examined histopathologically.; Results: The study included 246 patients with breast cancer: 196 were in the normal glucose group and 50 were in the elevated glucose group. In the normal glucose group, 68% of the tumors were left-sided and 32% were right-sided, while all tumors in the elevated glucose group were left-sided. This difference was statistically significant (P < 0.001). Tumor size, Ki-67, and the number of positive lymph nodes were not associated with blood glucose in patients with breast cancer (P > 0.05 for all). However, blood glucose was correlated with age in this population. Correlation analyses revealed that blood glucose was positively correlated with age (r = 0.23, P < 0.001). Additionally, Ki-67 was correlated with tumor size (r = 0.14, P = 0.03) and age (r = -0.18, P = 0.005).; Conclusion: Our study highlighted the complex interplay between metabolic factors, such as fasting glucose levels, and breast cancer characteristics. Elevated glucose levels were associated with older age. The significant association between tumor laterality and glucose levels underscores the need for further investigation into the collective influence of metabolic and anatomical factors on breast cancer development and progression.; (©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.) |
| Competing Interests: | Conflict-of-interest statement: All authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. |
| References: | Sci Rep. 2022 Aug 4;12(1):13377. (PMID: 35927418); Int J Cancer. 2007 Aug 15;121(4):856-62. (PMID: 17397032); BMC Cancer. 2019 Feb 21;19(1):165. (PMID: 30791870); Front Oncol. 2019 Nov 22;9:1290. (PMID: 31824862); Postgrad Med. 2024 Jun;136(5):496-503. (PMID: 38921178); Medicine (Baltimore). 2016 Dec;95(49):e5602. (PMID: 27930583); Diabetes Care. 2022 Jan 1;45(Suppl 1):S17-S38. (PMID: 34964875); J Clin Med. 2020 Jun 02;9(6):. (PMID: 32498398); Biosci Rep. 2019 Jun 14;39(6):. (PMID: 31142626); Front Cell Dev Biol. 2021 Sep 06;9:728759. (PMID: 34552932); JNCI Cancer Spectr. 2024 Apr 30;8(3):. (PMID: 38718185); Front Oncol. 2021 Feb 25;11:628359. (PMID: 33718202); J Clin Med. 2023 Sep 13;12(18):. (PMID: 37762893); Cancer Manag Res. 2018 Nov 29;10:6549-6554. (PMID: 30568509); Cancer Manag Res. 2014 Apr 16;6:191-203. (PMID: 24790468); JAMA Oncol. 2015 Aug;1(5):611-21. (PMID: 26182172); J Exp Clin Cancer Res. 2019 Jul 23;38(1):327. (PMID: 31337431); PLoS One. 2014 Apr 16;9(4):e94815. (PMID: 24740002); Endocrinology. 2018 Nov 1;159(11):3801-3812. (PMID: 30215698); Cancer Causes Control. 1996 Sep;7(5):539-43. (PMID: 8877052); Cancer Causes Control. 2004 Sep;15(7):637-45. (PMID: 15280621) |
| Contributed Indexing: | Keywords: Breast cancer; Diabetes mellitus; Hyperglycemia; Prognosis; Relationship |
| Entry Date(s): | Date Created: 20260112 Date Completed: 20260112 Latest Revision: 20260114 |
| Update Code: | 20260130 |
| PubMed Central ID: | PMC12781624 |
| DOI: | 10.5493/wjem.v15.i3.108318 |
| PMID: | 41523761 |
| Database: | MEDLINE |
Journal Article